Dr. rer. nat. Martin Schäfer

Programme Area 2, Scientists

Pharmacoepidemiology

Scientific background

Scientific Career

Since 2021
Principal Investigator of the RABBIT register, Pharmacoepidemiology, Programme Area Epidemiology and Health Services Research, DRFZ Berlin

Since 2017
Senior Statistician, Pharmacoepidemiology, Programme area Epidemiology and Health Services Research, DRFZ Berlin

2015
Doctoral Thesis: „Finite Bayesian mixture models with applications in spatial cluster analysis and bioinformatics”

2013 – 2016
Research assistant, Mathematical institute, Heinrich Heine University, Düsseldorf

2009 – 2013
Research assistant, Department of Statistics, TU Dortmund University, Dortmund

Education

2002 – 2009
Diploma in Statistics, TU Dortmund University, Dortmund

Professional Activities

Peer reviewing activity (last 5 years): Annals of the Rheumatic Diseases, Lancet Rheumatology, Journal of Rheumatology, RMD Open, Zeitschrift für Rheumatologie

Memberships

German Region of the International Biometrical Society

Projects

Go to end of slider

Joint financing
Joint grant

RABBIT Rheumatoid arthritis: observation of biologics therapy

BMBF

LinKMedR – Integrating Cancer Registry Data with Other Medical Registries

BMBF

TARISMA (sub-project 4): Investigation of treatment options and disease progression in patients with rheumatoid arthritis and chronic concomitant diseases

Go to beginning of slider

Selected publications

Gehe zum Ende des Sliders

Meißner Y, Schäfer M, Albrecht K, Kekow J, Kekow J, Zinke S, Tony HP, Strangfeld A.

Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register.

RMD Open. 2023 Oct;9(4):e003489. doi: 10.1136/rmdopen-2023-003489. PMID: 37880180; PMCID: PMC10603345.

Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register.

Machado PM, Schäfer M, Mahil SK, Liew JW, Gossec L, Dand N, Pfeil A, Strangfeld A, Regierer AC, Fautrel B, Alonso CG, Saad CGS, Griffiths CEM, Lomater C, Miceli-Richard C, Wendling D, Alpizar RD, Wiek D, Mateus EF, Sirotich E, Soriano ER, Ribeiro FM, Omura F, Rajão MF, Santos H, Dau J, Barker JN, Hausmann JS, Hyrich KL, Gensler LS, Silva L, Jacobsohn L, Carmona L, Pinheiro MM, Zelaya MD, Severina M, Yates M, Dubreuil M, Gore-Massy M, Romeo N, Haroon N, Sufka P, Grainger R, Hasseli R, Lawson-Tovey S, Bhana S, Pham T, Olofsson T, Bautista-Molano W, Wallace ZS, Yiu ZZN, Yazdany J, Robinson PC, Smith CH.

Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries.

Ann Rheum Dis. 2023 May;82(5):698-709. doi: 10.1136/ard-2022-223499. Epub 2023 Feb 14. PMID: 36787993.

Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries.

Regierer AC, Hasseli R, Schäfer M, Hoyer BF, Krause A, Lorenz HM, Pfeil A, Richter JG, Schmeiser T, Schulze-Koops H, Strangfeld , Voll RE, Specker C, Mueller-Ladner U.

TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD.

RMD Open. 2021 Oct;7(3):e001896. doi: 10.1136/rmdopen-2021-001896.

TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD.

Machado PM, Schäfer M, Strangfeld (Ersthelfer) A, Gossec L, Gianfrancesco MA, Lawson-Tovey S, Mateus EF, Carmona L, Hyrich KL, Robinson PC, Yazdany J.

Response to: 'Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry' by Arnaud and Devilliers.

Ann Rheum Dis. 2023 May;82(5):e114. doi: 10.1136/annrheumdis-2021-220058. Epub 2021 Feb 18. PMID: 33602795.

Response to: 'Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry' by Arnaud and Devilliers.

Strangfeld A, Schäfer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L, Mateus EF, Richez C, Santos MJ, Schmajuk G, Scirè CA, Sirotich E, Sparks JA, Sufka P, Thomas T, Trupin L, Wallace ZS, Al-Adely S, Bachiller-Corral J, Bhana S, Cacoub P, Carmona L, Costello R, Costello W, Gossec L, Grainger R, Hachulla E, Hasseli R, Hausmann JS, Hyrich KL, Izadi Z, Jacobsohn L, Katz P, Kearsley-Fleet L, Robinson PC, Yazdany J, Machado PM.